Phosplatin Therapeutics was formed to develop and commercialize phosphaplatins, a family of small-molecule compounds designed to replace the prior generations of platinum-based therapies in the treatment of cancer.

Platinum therapies are used by 50% or more of cancer patients worldwide – they are in many ways the backbone of medical oncology.

The phosphaplatin family of compounds is the result of nearly 30 years of investigation by Dr. Rathindra N. Bose, who is Chairman of the company’s Scientific Advisory Board, and Vice Chancellor for Research at the University of Houston.


Since inception, the company has built a robust data package through a variety of investigations of these novel compounds, and has proven their superior safety and efficacy in pre-clinical models. We are engaged with collaborators in six countries, and expect to launch out first-in-human clinical trials in 2014.

Our aim is to bring these agents to the market as quickly as possible, providing a safe, effective and affordable new therapy to cancer patients around the world.